Xu Huimin, Piao Linghua, Wu Yundi, Liu Xiande
School of Life Sciences, Hainan University, Haikou, China.
Department of Physiology, Hainan Medical University, Haikou, China.
Front Bioeng Biotechnol. 2022 Sep 29;10:996055. doi: 10.3389/fbioe.2022.996055. eCollection 2022.
Bacteria-mediated cancer immunotherapy (BCI) inhibits tumor progression and has a synergistic antitumor effect when combined with chemotherapy. The anti- or pro-tumorigenic effects of interferon-γ (IFN-γ) are controversial; hence, we were interested in the antitumor effects of IFN-γ/BCI combination therapy. Here, we demonstrated that IFN-γ increased the tumor cell killing efficacy of attenuated by prolonging the survival of tumor-colonizing bacteria blockade of tumor-infiltrating neutrophil recruitment. In addition, IFN-γ attenuated -stimulated immune responses by stimulating tumor infiltration by M1-like macrophages and CD4 and CD8 T cells, thereby facilitating tumor eradication. Taken together, these findings suggest that combination treatment with IFN-γ boosts the therapeutic response of BCI with S. tΔppGpp, suggesting that IFN-γ/BCI is a promising approach to immunotherapy.
细菌介导的癌症免疫疗法（BCI）可抑制肿瘤进展，与化疗联合使用时具有协同抗肿瘤作用。干扰素-γ（IFN-γ）的抗肿瘤或促肿瘤作用存在争议；因此，我们对IFN-γ/BCI联合疗法的抗肿瘤作用感兴趣。在此，我们证明，IFN-γ通过延长肿瘤定植细菌的存活时间、阻断肿瘤浸润性中性粒细胞募集，提高了减毒细菌的肿瘤细胞杀伤效力。此外，IFN-γ通过刺激M1样巨噬细胞、CD4和CD8 T细胞浸润肿瘤，减弱了细菌刺激的免疫反应，从而促进肿瘤根除。综上所述，这些发现表明，IFN-γ联合治疗可增强BCI与鼠伤寒沙门氏菌ΔppGpp的治疗反应，提示IFN-γ/BCI是一种有前景的免疫治疗方法。
